Skip to main content
SpringerLink
Log in

Purin-6-yltrimethylammonium chloride: A new purine antimetabolite

  • Kurze Mitteilungen
  • Published:
Experientia Aims and scope Submit manuscript

Zusammenfassung

Purin-6-yltrimethylammoniumchlorid wurde synthetisiert. Es erwies sich als ein hämopoetisch toxischer Antimetabolit, wirksam gegen Ehrlich Ascites-Tumor, DC5- und Ca 755-Mäusekrebs.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Author information

Authors and Affiliations

  1. Oncology Division, Detroit Institute of Cancer Research and Henry Ford Hospital, Detroit, Michigan, USA

    J. P. Horwitz & V. K. Vaitkevicius

Authors
  1. J. P. Horwitz
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. V. K. Vaitkevicius
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

Supported in part by grants CY-2903 aud CY-4519 from the National Cancer Institute of the U.S.P.H.S.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Horwitz, J.P., Vaitkevicius, V.K. Purin-6-yltrimethylammonium chloride: A new purine antimetabolite. Experientia 17, 552–553 (1961). https://doi.org/10.1007/BF02156417

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02156417

Keywords

Search

Navigation